Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Trial Profile

A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs IRX 2 (Primary) ; Cyclophosphamide; Indometacin; Omeprazole; Zinc
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms INSPIRE
  • Sponsors IRX Therapeutics
  • Most Recent Events

    • 07 Nov 2018 According to a Brooklyn ImmunoTherapeutics media release, results for this trial are expected in mid-2020
    • 31 Aug 2018 Biomarkers information updated
    • 16 Feb 2018 This trial was Discontinued in Spain, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top